Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is developing RVX-208 for the treatment of atherosclerosis. RVX’s business model is to seek strategic opportunities through early alliance partnerships with the potential to bring its technology platforms to successful commercialization. For further information, visit the company’s Web site at www.resverlogix.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: